Skip to main content

Legend Biotech Corp ADR(LEGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low17.48
Day High19.15
Open:17.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Legend Biotech Corp ADR

Select a category then submit the form to load news
Tipranks
Oppenheimer Reaffirms Their Buy Rating on Legend Biotech (LEGN)
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Motley Fool
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model
Tipranks
Legend Biotech Names Veteran Finance Executive Gareth Kung to Board and Audit Chair Role
Tipranks
Legend Biotech (LEGN) Gets a Buy from Barclays
Tipranks
Legend Biotech Reshapes Board, Appoints GenScript Chairman Robin Meng as Director
Tipranks
Goldman Sachs Keeps Their Buy Rating on Legend Biotech (LEGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Johnson & Johnson (JNJ)
Tipranks
Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Legend Biotech (LEGN)
Tipranks
Legend Biotech Announces Preliminary Q4 2025 CARVYKTI Sales of Approximately $555 Million
GlobeNewswire
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Tipranks
Piper Sandler Remains a Buy on Legend Biotech (LEGN)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Teva Pharmaceutical (TEVA)
Tipranks
Legend Biotech Signals 2026 Profitability Push and CARVYKTI Expansion in Updated J.P. Morgan Presentation
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Legend Biotech Marks 10,000 CARVYKTI Patients and Ramps Up Cell Therapy Capacity Ahead of 2026 Profit Push
GlobeNewswire
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
Motley Fool
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
Motley Fool
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
GlobeNewswire
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tipranks
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY)
Tipranks
RBC Capital Keeps Their Buy Rating on Legend Biotech (LEGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Legend Biotech (LEGN) and Caris Life Sciences, Inc. (CAI)
Tipranks
Legend Biotech Unveils Promising CARVYKTI® Data at ASH 2025
Tipranks
RBC Capital Remains a Buy on Legend Biotech (LEGN)
GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Tipranks
Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM), Legend Biotech (LEGN) and Immuneering (IMRX)
Tipranks
Legend Biotech’s Q3 2025: Strong CARVYKTI® Sales
Tipranks
Legend Biotech’s Earnings Call Highlights Growth and Challenges
GlobeNewswire
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Tipranks
Legend Biotech Reports Strong Q3 2025 Results and CARVYKTI® Progress

Profile

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.